Shares of Corium International, Inc. (NASDAQ:CORI) have earned an average rating of “Buy” from the nine analysts that are covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $12.20.
Several equities analysts have recently weighed in on the stock. BidaskClub cut shares of Corium International from a “buy” rating to a “hold” rating in a research note on Thursday, August 3rd. Jefferies Group LLC reiterated a “buy” rating and issued a $8.00 price objective on shares of Corium International in a research note on Wednesday, July 19th. Zacks Investment Research cut shares of Corium International from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. ValuEngine cut shares of Corium International from a “hold” rating to a “sell” rating in a research note on Thursday, August 24th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $13.00 price objective on shares of Corium International in a research note on Sunday, September 17th.
Corium International (CORI) traded up 0.18% during mid-day trading on Friday, hitting $10.85. 137,959 shares of the stock traded hands. Corium International has a 1-year low of $2.67 and a 1-year high of $11.00. The company’s 50 day moving average price is $8.44 and its 200-day moving average price is $6.67. The stock’s market cap is $387.80 million.
Corium International (NASDAQ:CORI) last issued its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.13). Corium International had a negative return on equity of 673.17% and a negative net margin of 145.60%. The business had revenue of $8.11 million during the quarter, compared to the consensus estimate of $8.71 million. Analysts predict that Corium International will post ($1.69) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This piece of content was posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/09/23/corium-international-inc-cori-given-consensus-recommendation-of-buy-by-brokerages.html.
In other Corium International news, CAO Timothy D. Sweemer sold 15,488 shares of the firm’s stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $7.82, for a total transaction of $121,116.16. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Parminder Singh sold 30,415 shares of the firm’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $7.59, for a total transaction of $230,849.85. Following the sale, the insider now owns 30,762 shares in the company, valued at approximately $233,483.58. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 91,953 shares of company stock worth $705,258. 46.50% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Broadfin Capital LLC raised its stake in Corium International by 45.2% during the 1st quarter. Broadfin Capital LLC now owns 2,787,121 shares of the biopharmaceutical company’s stock worth $11,650,000 after acquiring an additional 867,400 shares during the period. Perceptive Advisors LLC bought a new stake in Corium International during the 1st quarter worth approximately $11,096,000. AWM Investment Company Inc. raised its stake in Corium International by 1,125.9% during the 1st quarter. AWM Investment Company Inc. now owns 2,451,700 shares of the biopharmaceutical company’s stock worth $10,248,000 after acquiring an additional 2,251,700 shares during the period. Royce & Associates LP raised its stake in Corium International by 208.4% during the 1st quarter. Royce & Associates LP now owns 548,464 shares of the biopharmaceutical company’s stock worth $2,293,000 after acquiring an additional 370,600 shares during the period. Finally, Stonepine Capital Management LLC bought a new stake in Corium International during the 2nd quarter worth approximately $3,085,000. Institutional investors own 90.14% of the company’s stock.
Corium International Company Profile
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.